Karyopharm Therapeutics | Ativos





Ativos Alterar Data
AbbVie USD 133.96B 62M 2025-12
Abbott USD 86.71B 2.53B 2025-12
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
BioCryst Pharmaceuticals USD 446.42M 10.76M 2025-09
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Incyte USD 6.96B 627.62M 2025-12
J&J USD 199.21B 6.39B 2025-12
Karyopharm Therapeutics USD 96.23M 8.65M 2025-09
MacroGenics USD 270.76M 25.34M 2025-09
Merck USD 129.55B 12.02B 2025-09
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Novartis USD 107.29B 2.89B 2025-09
Novartis USD 107.29B 2.89B 2025-09
Pfizer USD 208.73B 2.64B 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Takeda JPY 15.41T 938.47B 2025-12
Tectonic Therapeutic USD 277M 18.31M 2025-09
TG Therapeutics USD 1.06B 38.23M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Xencor USD 875.5M 6.68M 2025-12


Karyopharm Therapeutics Ativos - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2026.